Kungani umdlavuza udluliselwa kalula esibindi?

Yabelana ngalokhu okuthunyelwe

A Duke University study has shown that metastatic cancer cells can regulate the metabolic function to reproduce in new organs. Cells derived from colorectal cancer have changed their metabolic habits, making full use of fructose in the liver as much as possible. Once the cancer has spread to different parts of the body, the cancer becomes more deadly, but the treatment does not consider the location of its metastasis and is treated according to the original site. From a genetic point of view, umdlavuza colon is colon cancer, no matter where it is transferred. But this does not mean that it cannot respond to the new environment. This response may not be genetic, but metabolic. When cancer cells enter the liver, they are like a child in a candy store, using this abundant new energy to create more cancer cells. In order to feed on fructose, cancer cells need to produce more enzymes that can break down fructose, called ALDOB. Once cancer cells find out how to turn fructose back on, cancer cells will lose control and proliferate. In addition to providing reasons for how cancer proliferates after metastasis, this discovery can also lead to new therapies for metastatic cells. For example, avoiding the use of fructose by eating natural non-processed foods and providing drugs that block the metabolism of fructose may prevent cancer from spreading from other organs to the liver. Since pharmaceutical companies have recently developed new drugs for fructose metabolism to treat metabolic diseases, this crossover therapy may not be far away. Doctors can usually remove the primary tumor. But understanding the causes of cancer metastasis and how to adapt to a new home may provide us with a new weapon against cancer.

Bhalisa ku-Newsletter yethu

Thola izibuyekezo futhi ungalokothi uphuthelwe ibhulogi evela kuCancerfax

Okuningi Okuzohlolwa

I-Lutetium Lu 177 dotatate igunyazwe yi-USFDA yeziguli zezingane ezineminyaka engu-12 nangaphezulu nge-GEP-NETS
Cancer

I-Lutetium Lu 177 dotatate igunyazwe yi-USFDA yeziguli zezingane ezineminyaka engu-12 nangaphezulu nge-GEP-NETS

I-Lutetium Lu 177 dotatate, ukwelashwa okuyisimangaliso, isanda kuthola imvume evela kwa-US Food and Drug Administration (FDA) yeziguli zezingane, okumaka ingqopha-mlando ku-oncology yezingane. Lokhu kugunyazwa kumelele ukukhanya kwethemba ezinganeni ezilwa nezimila ze-neuroendocrine (NETs), uhlobo lomdlavuza oluyivelakancane kodwa oluyinselele oluvame ukufakazela ukumelana nemithi evamile.

I-Nogapendekin alfa inbakicept-pmln igunyazwe yi-USFDA yomdlavuza wesinye ongasabeli we-BCG ongaphenduli.
Umdlavuza wesibeletho

I-Nogapendekin alfa inbakicept-pmln igunyazwe yi-USFDA yomdlavuza wesinye ongasabeli we-BCG ongaphenduli.

“I-Nogapendekin Alfa Inbakicept-PMLN, i-immunotherapy enoveli, ibonisa isithembiso ekwelapheni umdlavuza wesinye uma kuhlanganiswa nokwelashwa kwe-BCG. Le ndlela yokusungula iqondise izimpawu ezithile zomdlavuza ngenkathi isebenzisa impendulo yamasosha omzimba, ithuthukisa ukusebenza kahle kwemithi yokwelapha yendabuko efana ne-BCG. Izivivinyo zemitholampilo zembula imiphumela ekhuthazayo, ekhombisa imiphumela ethuthukisiwe yesiguli kanye nentuthuko engaba khona ekulawuleni umdlavuza wesinye. Ukusebenzisana phakathi kwe-Nogapendekin Alfa Inbakicept-PMLN kanye ne-BCG kumemezela inkathi entsha yokwelashwa komdlavuza wesinye.”

Dinga usizo? Ithimba lethu likulungele ukukusiza.

Sifisela ukululama okusheshayo kothandekayo wakho futhi oseduze.

Qala ingxoxo
Siku-inthanethi! Xoxa Nathi!
Skena ikhodi
Sawubona,

Siyakwamukela kuCancerFax!

ICancerFax iyinkundla yokuphayona ezinikele ekuxhumaniseni abantu ababhekene nomdlavuza oseqophelweni eliphezulu ngemithi yokwelapha yamangqamuzana efana ne-CAR T-Cell therapy, ukwelashwa kwe-TIL, nezivivinyo zomtholampilo emhlabeni wonke.

Sazise ukuthi yini esingakwenzela yona.

1) Ukwelashwa komdlavuza phesheya?
2) Ukwelashwa kwe-CAR T-Cell
3) Umuthi wokugomela umdlavuza
4) Ukubonisana ngevidiyo eku-inthanethi
5) Ukwelashwa kweProton